Canada markets open in 3 hours 41 minutes

Bausch + Lomb Corporation (BLCO)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
14.71+0.01 (+0.07%)
At close: 04:00PM EDT
14.71 0.00 (0.00%)
After hours: 04:05PM EDT

Bausch + Lomb Corporation

520 Applewood Crescent
Vaughan, ON L4K 4B4
(905) 695-7700

IndustryMedical Instruments & Supplies
Full Time Employees13,300

Key Executives

NameTitlePayExercisedYear Born
Mr. Brenton L. Saunders J.D.CEO & Chairman10.13MN/A1970
Mr. Osama A. EldessoukyExecutive VP & CFO1.32MN/A1972
Mr. A. Robert D. BaileyExecutive VP & Chief Legal Officer1.16MN/A1963
Dr. Yehia Hashad M.D.Executive VP of Research & Development and Chief Medical officer1.23MN/A1968
Mr. Andrew StewartPresident of Global Pharmaceuticals & International Consumer1.37MN/A1975
Mr. Alan Waterhouse CPFA, MBAExecutive VP and Chief Supply Chain & Operations OfficerN/AN/A1960
Mr. Frederick J. MunschSenior VP, Controller & Chief Accounting OfficerN/AN/A1971
Mr. Jonathon L. KellermanChief Compliance OfficerN/AN/AN/A
T.J. CrawfordChief Communications OfficerN/AN/AN/A
Dr. Manisha A. Narasimhan Ph.D.Chief Corporate Development & Digital OfficerN/AN/A1977
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.

Corporate Governance

Bausch + Lomb Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.